The small blue circles show the IC-volume (mean of left and right) from 72 males and the small red squares from 51 females as a function of age. by Pingling Kwok (14896191)

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…”

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…”

Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…”

Summary of significant treatment × time effect. by Wensheng Xiao (16557866)

Table 2_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx by Tengxiang Zhao (20749475)

“…Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.</p>…”

Table 1_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx by Tengxiang Zhao (20749475)

“…Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.</p>…”

Significant condition. by Junxia Zhou (14381598)

“…Micro-cracks appeared in the cemented body by Day 7, resulting in a slight decrease in strength (3.92%) from Day 3 to Day 7. The formation of well-developed needle-like AFt, C-(A)S-H gel, and small-volume plate-like CH contributed to uniform cementation and a denser structure. …”

No significant diurnal rhythmicity of short chain fatty acids in the blood was observed. by Weiran Shan (16969688)

Pretreatment of BM-MSCs improves the survival rate and incidence of DCS. by Chen Lu (135200)

Effect of BM-MSCs in improving DCS induced lung injury. by Chen Lu (135200)

Compression index of improved red clay. by Quan Shen (37564)

Subjects:

Compressibility modulus of improved red clay. by Quan Shen (37564)

Subjects:

Compressive strain of improved red clay. by Quan Shen (37564)

Subjects:

Task 1 two-way ANCOVA significant results. by Mucahit Gemici (21519313)

Task 2 one-way ANCOVA significant results. by Mucahit Gemici (21519313)

Summary of significant single-arm time effect. by Wensheng Xiao (16557866)

Demonstration of decreased Aβ accumulation by DA-9601 treatment. by Mijung Lee (397790)

AdMSC-EVs enhanced colony formation and migration of LECs and decreased proliferation. by Xiaoqin Li (1399105)

The linearly decreasing convergence factor a. by Junhao Wei (6816803)